SPEAKER | Elizabeth Nabel, M.D., President, Brigham and Women’s Hospital

Artificial intelligence may help inform personalized medicine in the future by perceiving which genes, proteins and other biological characteristics contribute to human disease. During this session, a diverse panel will discuss how artificial intelligence may accelerate drug development, improve clinical decision support and drive patient outcomes — and what that might mean for the future of health care.

MODERATOR | Colin Hill, Chairman, CEO, Co-Founder, GNS Healthcare

• Data, right data
• Investment is it in data acquisition or in AI
• AI is not taking over, data is critical
• Predictionds for 2025

Tom Miller, Managing Partner, GreyBird Ventures LLC

• algorithms are behind the firewall of the Hospital, for privacy. the patient’s identity is not of central point, privacy is the key
• Meta ontologies –  not ready yet
• Validation of AI algorithms
• India shortage of Radiologists
• China is a huge market – AI will do functions of MDs
• Oncology will lead the way in innovations

Gregg Talbert, Ph.D., Global Head of Digital and Personalized Health Care Partnering, Roche

• AI applied to capture unusual movement allowing to detect a forthcoming neurological event.
• Data is enough to get started on mutations
• Data falls short on Patient follow up (longitudinal data on Patients) curation of EMR IS NOT AN EASY OR AUTOMATED PROCESS, IMAGING SPACE: CURATION OF IMAGES is quite a problem,
• lack of productivity in the Healthcare system: records on transfer of patient to hospitals
• Clinical Trial data for drug approval, also for future use of the analyzed data
• In developing markets – solutions needs to be not a replication of the Western World medicine
• Prediction: Data problem will be resolved in some areas, drugs developed by synthethic biologytaget to diseases drugs developed by AI
• Patients will drive processes in Healthcare
• Roche participates in data sharing and transfer protocols

Darrell M. West, Ph.D., Vice President of Governance Studies and Director of Center for Technology Innovation, Douglas Dillon Chair in Governance Studies, The Brookings Institution

• Interest in AI and in particular: Health care large part of the economy Technologies:
• Radiology: SW used in detection of disease
• Personalized Medicine and AI
• Data mining of Text using AI
• Vital signs monitoring – providers can spot Arrhythmias earlier
• Data centers have rich data , data analysis is important in Financial institutions for upselling instruments. In healthcare there is room as well
• Future of Work book authored by Dr. West – augmentation of skills not replacement of
• NY, Cold Spring: Local vs National, local progressive regulation is worrisome, pattern will migrate from NY to MA, to CA, OR, WA.
• Mobile technology in Africa is advance: Global money, smart phones
• 2015: AI will transform other technologies: Communications, smart phones,

SPEAKER | David King, J.D., Chairman, CEO, LabCorp

• Clinical outcomes at reduced cost
• PM – field with success
• challenges faced by PM
• BRCA  gene at Breast Cancer patient – drug approved by FDA for this cases only
• Genetic conseling assist physicians
• What is diagnostics: NOT ONLY a test,
• NGS is part of diagnostics strategy – enormous potential vs biopsy
• Genetic testing improve outcomes
• Insurance covers BRCA I AND BRCAII – ONLY
• COVERAGE OF GENETIC TESTING : RANDOMIZED, CONTROLLED TRIALS, published in peer reviewed literature and the test will prolong life – Test do not prolong life, therefore, the test does not improve outcomes – drugs do !!!
• PM individualized treatment for a specific disease
• drug improve outcomes
• Validity od data is fundamental, credibility of testing
• Right drug to right patient
• Migraine drug to be used
• Non respondent – further researched
• MDs understanding, confidence of results
• PM Promise: close education GAP,
• convene on VALUE for individual cases not populations
• assess value among initiatives
• PM – beyond Oncology
• Regulation of diagnostics

The U.S. Food and Drug Administration and the U.S. Centers for Medicare and Medicaid Services have been working for over a decade to develop regulatory and reimbursement pathways that promote the development of innovative diagnostic tests. Many observers, however, believe the current regulatory and reimbursement landscape still limits the field. This panel of business leaders will discuss the extent to which the existing frameworks and proposed policies may help or hinder personalized medicine.

MODERATOR | Joseph V. Ferrara, CEO, Boston Healthcare Associates

• Regulatory action for reimbursement of test
• new categories of tests: new payment if Innovation, PLA codes, 45 months approval, CPT codes

3. Michael Doherty, Senior Vice President, Head of Product Development, Head of Research & Development, Foundation Medicine – ex Genentech/Roche

• Operate in regulated environment, how to establish a company for long term
• companion diagnostics
• payment collection is the burden of the company
• challenge for future products, investment process changes

Julie Khani, President, American Clinical Laboratory Association

• FDA will establish a center for Diagnostics, proposal for pre-certification like in Medical devices
• congress is involved in the decision making
• Labs are prohibited from providing the data

2. Kimberly Popovits, Chairman of the Board, CEO, President, Genomic Health – Oncology, Breast cancer molecular diagnostics

• Genomic testing saved the Health care System billions of dollars
• Genomic testing will not be placebo, 12 years study controlled arms
• proprietary test vs. test offered by all labs — different markets
• Utility agreed upon like “MedicalDevicesInnovation.org”
• demonstrate a pathway of product development that was already followed

4. Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific

Light refreshments provided.

Sponsored By

Advancing a medical paradigm that focuses on the unique characteristics of each patient will require, by definition, that patients from diverse backgrounds participate in the medical studies that advance our understanding of disease. Also critical is the need to ensure that those patients have access to personalized care informed by those studies. During this session, four panelists will discuss the effort to ensure that all patient populations benefit equally from personalized medicine.

MODERATOR | Donna R. Cryer, J.D., President, CEO, Global Liver Institute

• diversity of the Genome initiative for inclusion and generalizability

Vence L. Bonham, Jr., J.D., Senior Advisor, Director on Genomics and Health Disparities, U.S. National Human Genome Research Institute

• Genomics data is of European dissents no diversity
• minority populations not represented
• sland populations not represented
• hispanics not represented proportionally to their share in the population

Alex J. Carlisle, Ph.D., Chairman, CEO, National Alliance Against Disparities in Patient Health

Adolph P. Falcón, Executive Vice President, National Alliance for Hispanic Health

• community based organization 50 million
• improving healthcare access
• improve inclusion in science, no advancement in 45 years
• Hard to reach through – academic language of research protocols is not understood by patients
• common language, inclusion, diffusion to the field of the models that were developed to work
• PROTOCOL TO BE IN ENGLISH AND IN SPANISH
• OPERATES IN 24 CITIES
• Funding needed to find which clinical trials support inclusion “data not available”
• Community work must be married with Health initiatives

Edward Tepporn, Executive Vice President, Asian & Pacific Islander American Health Forum

• since 1985 minorities education
• all surveys conducted in English, Asian American
• access to affordable health care
• services to accommodate services for communities of Asian American
• encourage NIH to conduct studies on Asian American

SPEAKER | Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

• Science is better than ever
• Technologies: AI, Countries with platforms
• Regulatory framework, reproducibility of results
• Taking care of people, standardization of data analysis
• Inclusion, populations that historically were excluded

Avenue of the Arts
465 Huntington Avenue
Boston, MA 02115

Sponsored by